Atossa 疗法公司宣布，其将在 2026 年美国临床肿瘤学会（ASCO）年会上公布的摘要，重点展示了其候选药物 (Z)-Endoxifen 在多种雌激素受体 1（ESR1）突变中的活性数据，并提供了正在进行的 Evangeline II 期临床试验的最新信息。
摘要内容揭示了 (Z)-Endoxifen 作为一种选择性雌激素受体降解剂，在临床前模型中对一系列 ESR1 突变体表现出显著的抗增殖活性。这些发现支持了该药物在治疗对标准内分泌疗法产生耐药性的雌激素受体阳性乳腺癌方面的潜在价值。
同时，摘要也概述了 Evangeline II 期试验的设计与当前进展。该试验旨在评估 (Z)-Endoxifen 在特定乳腺癌患者群体中的疗效与安全性，相关数据将进一步阐明该疗法的临床前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.